QLGN insider filings
Qualigen Therapeutics, Inc. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-08-04. Screen QLGN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for QLGN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Qualigen Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-08-04 | 4 | Ritter Ira E. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | ARSHAD TARIQ — SVP/Chief Medical Officer | Grant/award (A): 102,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Abdul-Ahad Wajdi — Vice President, R & D, CSO | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Lotz Christopher L. — Vice President of Finance, CFO | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | David Richard A. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Poirier Michael S. — Chairman and CEO, Director | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | BROIDRICK AMY S. — President/CSO, Director | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Korenberg Matthew E — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Sinha Shishir K. — VP, COO & Secretary | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | Kruger Kurt H — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-08-04 | 4 | EMERY SIDNEY W JR — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Poirier Michael S. — Chairman and CEO, Director | Purchase (P): 30,000 @ $0.57 | EDGAR |
| 2022-06-15 | 4 | BROIDRICK AMY S. — President/CSO, Director | Purchase (P): 30,000 @ $0.62 | EDGAR |
| 2021-12-10 | 4 | BROIDRICK AMY S. — President/ChiefStrategyOfficer, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2021-12-10 | 4 | ARSHAD TARIQ — SVP/Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2021-08-20 | 4 | Kruger Kurt H — Director | Purchase (P): 4,000 @ $1.23 · Purchase (P): 4,000 @ $1.22 | EDGAR |
| 2021-05-18 | 4 | ARSHAD TARIQ — SVP/Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-04-26 | 4 | BROIDRICK AMY S. — EVP, Chief Strategy Officer, Director | Purchase (P): 4,500 @ $2.03 | EDGAR |
| 2021-04-21 | 4 | Poirier Michael S. — Chairman, CEO & President, Director | Purchase (P): 11,005 @ $1.80 | EDGAR |
| 2021-04-19 | 4 | Lotz Christopher L. — Vice President of Finance, CFO | Purchase (P): 2,700 @ $1.86 | EDGAR |
| 2020-12-30 | 4 | Kruger Kurt H — Director | Purchase (P): 4,000 @ $2.94 | EDGAR |
| 2020-12-29 | 4 | BROIDRICK AMY S. — Executive VP, CSO, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2020-12-08 | 4 | EMERY SIDNEY W JR — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2020-11-23 | 4 | Kruger Kurt H — Director | Purchase (P): 1,400 @ $3.55 · Purchase (P): 4,600 @ $3.46 | EDGAR |
| 2020-08-28 | 4 | BROIDRICK AMY S. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Qualigen Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Qualigen Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-297725 (S-1) — latest: Amendment (S-1/A), filed 2026-09-09
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=QLGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs